Short interest for Lantheus Holdings gives investors a sense of the degree to which investors are betting on the decline of Lantheus Holdings's stock. Short interest data is updated every two weeks.

Lantheus Holdings Stock (NASDAQ:LNTH), Short Interest Report

Lantheus Holdings

Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.

C.H. Robinson Worldwide - logo

News

Intraday Update

Markets

Movers

ASPN

BPMC

CHRW

CVNA

ENVX

GKOS

ITRI

LNTH

LUNG

MRNA

NOVA

PRDO

QCOM

TROX

C.H. Robinson Worldwide Posts Upbeat Results, Joins Avis Budget Group, Qualcomm, BorgWarner, Moderna And Other Big Stocks Moving Higher On Thursday

Long Ideas

Small Cap

Media

Trading Ideas

DDOG

MRVL

ONON

RDNT

SOFI

On CNBC’s &#34;Mad Money Lightning Round,&#34; Jim Cramer said  Marvell Technology, Inc. (NASDAQ: MRVL) reported a mixed quarter.

Cramer Calls Datadog &#39;Dynamite,&#39; Puts SoFi In Dog House: &#39;What The Heck Is Going On&#39;

Penny Stocks

ACVA

AGRX

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

ATNI

BBLG

BELFA

BZFD

DOCN

DPRO

EAST

ETSY

EZFL

GBNH

GSHD

INDV

KTOS

LCID

LRHC

MATV

MGPI

MNPR

MNTS

NVAX

NVDA

OCUL

QTWO

RELY

RILY

RIVN

ROOT

RXRX

SMCI

SNPS

SNPX

TRUE

VERO

Why Etsy Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Lantheus Holdings Inc

U.S. stocks were higher, with the Dow Jones index gaining over 50 points on Thursday.
Shares of C.H. Robinson Worldwide, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRW#NASDAQ">CHRW</a>) rose sharply during Thursday's session after the company reported better-than-expected <a href="https://www.benzinga.com/quote/CHRW/earnings">first-quarter financial results</a>.
C.H. Robinson Worldwide posted adjusted earnings of 86 cents per share, beating market estimates of 82 cents per share. The company's quarterly sales came in at $4.412 billion versus expectations of $4.269 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
C.H. Robinson Worldwide shares jumped 16.8% to $84.24 on Thursday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Aspen Aerogels, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>) jumped 37.5% to $20.92 after the company reported better-than-expected first-quarter financial results.</li>
<li>Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) rose 35.8% to $118.19 after the company announced upbeat quarterly results.</li>
<li>Enovix Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVX#NASDAQ">ENVX</a>) surged 27.1% to $8.27 after the company reported mixed first-quarter financial results.</li>
<li>Gannett Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GCI#NYSE">GCI</a>) rose 22.3% to $2.9519 following strong quarterly results.</li>
<li>Perdoceo Education Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRDO#NASDAQ">PRDO</a>) jumped 19.4% to $21.89 following upbeat results.</li>
<li>Pulmonx Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNG#NASDAQ">LUNG</a>) rose 19.2% to $9.20 after the company reported better-than-expected first-quarter financial results.</li>
<li>Benchmark Electronics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHE#NYSE">BHE</a>) surged 18.3% to $35.82 following better-than-expected quarterly results.</li>
<li>Pitney Bowes Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBI#NYSE">PBI</a>) rose 18% to $4.97 following strong quarterly results.</li>
<li>Rush Street Interactive, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSI#NYSE">RSI</a>) shares gained 17.4% to $7.53 after the company reported better-than-expected first-quarter financial results and issued FY24 revenue guidance above estimates.</li>
<li>Avis Budget Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAR#NASDAQ">CAR</a>) rose 15.7% to $109.62 after the company reported mixed first-quarter financial results.</li>
<li>Howmet Aerospace Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HWM#NYSE">HWM</a>) climbed 15.2% to $76.93 after the company reported better-than-expected first-quarter financial results.</li>
<li>Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) rose 15% to $4.0399 after the company reported better-than-expected first-quarter adjusted EPS results.</li>
<li>Valmont Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VMI#NYSE">VMI</a>) rose 14.4% to $237.65 after the company posted upbeat quarterly earnings and raised FY24 EPS guidance.</li>
<li>Blueprint Medicines Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) gained 13.7% to $107.81 after the company reported better-than-expected first-quarter results and raised FY24 revenue guidance.</li>
<li>Lantheus Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) surged 12.8% to $76.09 after the company reported better-than-expected first-quarter results and raised its FY24 adjusted EPS outlook.</li>
<li>Sprouts Farmers Market, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFM#NASDAQ">SFM</a>) climbed 12% to $72.08 after the company reported better-than-expected first-quarter EPS and sales.</li>
<li>Wayfair Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>) gained 11.7% to $56.53 after the company reported better-than-expected first-quarter financial results.</li>
<li>Tronox Holdings plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TROX#NYSE">TROX</a>) rose 10.8% to $18.94 following strong sales.</li>
<li>Kontoor Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KTB#NYSE">KTB</a>) gained 9.9% to $68.29 following better-than-expected quarterly results.</li>
<li>QUALCOMM Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) climbed 8.5% to $178.02 after the company reported better-than-expected second-quarter financial results, raised its dividend and issued third-quarter guidance.</li>
<li>Belden Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDC#NYSE">BDC</a>) gained 8.2% to $87.95 after the company reported mixed first-quarter earnings and announced the acquisition of Precision Optical Technologies.</li>
<li>Kellanova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/K#NYSE">K</a>) rose 8.1% to $61.60 following upbeat earnings.</li>
<li>Glaukos Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) gained 7.7% to $106.55 following strong sales.</li>
<li>Sealed Air Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEE#NYSE">SEE</a>) surged 7.7% to $34.60 after the company reported better-than-expected quarterly financial results.</li>
<li>BorgWarner Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWA#NYSE">BWA</a>) gained 7.7% to $35.39 following upbeat earnings.</li>
<li>Itron, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRI#NASDAQ">ITRI</a>) rose 7.4% to $98.39 following upbeat earnings.</li>
<li>IAC Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAC#NASDAQ">IAC</a>) gained 6.8% to $51.11 after it was announced the stock will join the S&amp;P SmallCap 600.</li>
<li>Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) shares jumped 6.5% to $118.75 following first-quarter results.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/05/38584879/apple-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">Apple Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a>

WIIM

Lantheus shares are trading higher after the company reported better-than-expected Q1 results and raised its FY24 adjusted EPS outlook.

Guidance

Lantheus Sees Q2 Revenue Of $380m - $390M Vs. $356.1M Est; Adj EPS Of $1.81 - $1.86 Vs. $1.66 Est.

Lantheus Raises FY24 Adj EPS Outlook From $6.50 - $6.70 To $7.00 - $7.20 Vs. $6.58 Est.

Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) reported quarterly earnings of $1.69 per share which beat the analyst consensus estimate of $1.54 by 9.74 percent. This is a 14.97 percent increase over earnings of $1.47 per share from the same period last year. The company reported quarterly sales of $370.00 million which beat the analyst consensus estimate of $348.45 million by 6.18 percent. This is a 23.01 percent increase over sales of $300.78 million the same period last year.

Earnings

Earnings Beats

Lantheus Holdings Q1 Adj $1.69 Beats $1.54 Estimate, Sales $370.00M Beat $348.45M Estimate

B. Riley Securities analyst Justin Walsh maintains Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) with a Buy and raises the price target from $95 to $99.

Price Target

Analyst Ratings

B. Riley Securities Maintains Buy on Lantheus Holdings, Raises Price Target to $99

On CNBC&rsquo;s &quot;Mad Money Lightning Round,&quot; Jim Cramer said Marvell Technology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrvl#NASDAQ">MRVL</a>) reported a mixed quarter. &quot;<a href="https://www.benzinga.com/news/24/03/37756021/marvells-latest-tech-leap-with-tsmc-a-2nm-chip-platform-set-to-transform-ai-infrastructure">We got to wait,&quot; he added. </a>
Last week, Marvell Technology unveiled a significant development in semiconductor technology through an expanded partnership with Taiwan Semiconductor Manufacturing Co (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tsm#NYSE">TSM</a>), launching the first-ever 2nm silicon intellectual property (IP) technology platform.
Cramer recommended buying Datadog, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ddog#NASDAQ">DDOG</a>), saying that it is a &quot;dynamite&quot; company. &quot;It is expensive, but they really know what they&rsquo;re doing,&quot; he noted.
On Feb. 13, Datadog posted upbeat sales for its fourth quarter, but issued FY24 EPS guidance below estimates. The company clocked fourth-quarter FY23 revenue growth of 26% year-on-year to $589.649 million, beating the consensus of $568.695 million.
When asked about Centrus Energy Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/leu#NYSE">LEU</a>), he said, &quot;Very speculative situation. I want you to buy the GE spinoff that&rsquo;s coming, it&rsquo;s Vernova. That has got nuke, and I love the balance sheet, and I love what the company&rsquo;s doing, and you want to be a little diversified.&quot;
On Feb. 8, Centrus Energy reported better-than-expected fourth-quarter financial results.
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a> 
Altimmune, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alt#NASDAQ">ALT</a>) is an &quot;absolute, without a doubt, high-risk stock, when you could have Eli Lilly (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lly#NYSE">LLY</a>),&quot; Cramer said.
Last month, Kerrisdale Capital announced a short position in the stock, claiming the company had little chance of competing against others in the GLP-1 space and calling it an &ldquo;<a href="https://www.benzinga.com/24/02/37102984/altimmune-stock-sinks-as-kerrisdale-capital-announces-short-position-obvious-dead-end">obvious dead end</a>.&rdquo;
When asked about Lantheus Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lnth#NASDAQ">LNTH</a>), he said, &quot;I&rsquo;ve been preferring RadNet (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rdnt#NASDAQ">RDNT</a>), because I think they&rsquo;ve got a better business model.&quot;
On March 4, Lantheus announced the FDA approval of DEFINITY for pediatric patients.
&quot;They were doing great, and then they did this convertible bond, and it just wrecked the stock,&quot; the &quot;Mad Money&quot; host said about SoFi Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sofi#NASDAQ">SOFI</a>). &quot;The stock has just been in the dog house ever since, and I don&rsquo;t like it when I tell people to buy a stock and it&rsquo;s staying in the dog house. We got to find out what the heck is going on there.&quot;
On March 5, SoFi Technologies announced a proposed $750 million convertible senior notes offering due 2029.
Cramer said On Holding AG (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/onon#NYSE">ONON</a>) had a &quot;controversial&quot; quarter. &quot;I am on the fence on On,&quot; he added.
<h3>Price Action</h3>
<ul>
<li>Shares of Marvell Technology gained 0.5% to close at $67.20 on Monday.</li>
<li>Datadog shares gained 0.4% to close at $120.87 on Monday.</li>
<li>Centrus Energy shares gained 1.4% to settle at $38.77.</li>
<li>Altimmune shares dipped 7.9% to settle at $9.08 on Monday.</li>
<li>Lantheus shares fell 2.8% to close at $56.52 on Monday.</li>
<li>Shares of SoFi rose 0.7% to settle at $7.08.</li>
<li>On Holding shares fell 0.4% to close at $33.10 on Monday.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/03/37780512/traeger-and-3-other-stocks-under-5-insiders-are-buying"> Traeger And 3 Other Stocks Under $5 Insiders Are Buying</a>
Image: Shutterstock

Cramer Calls Datadog 'Dynamite,' Puts SoFi In Dog House: 'What The Heck Is Going On'

<a href="https://www.globenewswire.com/Tracker?data=G3od7DmiT0iR1x0U-LOiJd3t_UMvG3SXAaHhyS59WXIw3RPqKquH_rSn94X6lVzP_JihIK1VpUIWSDlRBV7Un2pDc4ZRmtyHpa4oIxxWItd--ByEETH5Pb0kLCS0TUx0">Perspective Therapeutics, Inc.</a>&nbsp;("Perspective" or "the Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CATX#NYSE">CATX</a>), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the consummation of the acquisition of a state-of-the-art manufacturing facility and associated equipment and systems for the production of its 203Pb- and 212Pb-labeled radiopharmaceuticals. &nbsp;
Previously operated by Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>), the leading radiopharmaceutical-focused company, this 11,500 square foot facility, located in Somerset, New Jersey, has operated in compliance with both Part 212 and Part 211 of Title 21 of the Code of Federal Regulations (CFR) in the U.S., meeting Current Good Manufacturing Practice (cGMP) requirements. As a cGMP compliant facility, Perspective intends to utilize the facility to manufacture clinical supply of high quality 203Pb-labeled tumor-specific peptides to visualize and diagnose tumors, and 212Pb-labeled radiopharmaceuticals to treat target tumors with targeted alpha therapies (TAT). Moreover, with its three cGMP suites at the facility, Perspective expects to have the capacity to meet future clinical trial and commercial demands at major cancer treatment centers throughout the Northeastern U.S.
The facility acquisition is part of a series of strategic agreements with Lantheus that Perspective <a href="https://www.globenewswire.com/Tracker?data=rYJWAXIHzi5jsXXZMCIs5qtZ5BVjuScSErAHeFJDsvsLS--STqDM7HGYi6te1rTAW-ZS0mHUIUGU_kTizzl0byMPVaNqhmK-lV7uRjle-GSfHdZzwCuVya8rMDJJ2tNwPL3Vaaa58SsvJEa_njXlVg==">announced on</a> January 9, 2024, which included an initial equity investment in Perspective. In addition, on March 4, 2024, Perspective announced it had entered into an investment agreement to sell shares of the Company's common stock to certain accredited institutional investors for gross proceeds of $87.4 million, $57.4 million of which will be purchased by Lantheus upon the consummation of the transaction.
"We look forward to welcoming the exceptional talent at this facility and integrating them into our team," said Shane Cobb, Executive Vice President of Operations, Perspective Therapeutics. "The acquisition of this facility much earlier than initially planned is expected to allow us to move forward more quickly to deliver clinical and, if approved for commercialization, commercial doses. Given the 10.6-hour half-life for 212Pb lead, it is important that we have the infrastructure and personnel to support production of our radiopharmaceuticals, all within the vicinity of the patients we hope to impact. This is a significant milestone for Perspective as we build upon the progress we have made in establishing clinical manufacturing."
"We are thrilled to expand our manufacturing and supply chain infrastructure to include this facility capable of operating in compliance with Parts 212 and 211," said Thijs Spoor, Chief Executive Officer, Perspective Therapeutics. "The acquisition is a testament to our commitment to making our targeted alpha-particle therapies available to patients in critical need, and builds on our strategic expansion as we look to establish facilities in proximity to major treatment hubs in the U.S."
"We are excited for the opportunity to strengthen our strategic collaboration with Perspective Therapeutics," said Brian Markison, Chief Executive Officer, Lantheus. "We recognize the transformative potential of Perspective's alpha therapies and platform which we believe have the potential to improve efficacy, while minimizing toxicity across a range of tumor settings. We are pleased the Somerset facility will be used to manufacture these innovative product candidates."
About Part 211 and Part 212 Part 211 of Title 21 of the Code of Federal Regulations (CFR) outlines the Current Good Manufacturing Practice (cGMP) requirements for finished pharmaceutical products. It covers various aspects of pharmaceutical manufacturing, including facilities, equipment, controls, and processes to ensure the quality and safety of the final products. Part 212 of Title 21 of the CFR specifically pertains to the cGMP requirements for the manufacturing of positron emission tomography (PET) drugs. PET drugs are radiopharmaceuticals used in medical imaging, and Part 212 sets forth requirements tailored to their unique production processes and quality control measures. The main difference between Part 211 and Part 212 lies in their focus areas, with Part 212 catering to the specialized needs of PET drug manufacturing. Like drugs used for PET, Perspective anticipates that its 203Pb-labelled peptides will be regulated under Part 212. Like other manufactured drugs, Perspective anticipates that 212Pb-labelled peptides will be regulated under Part 211.

CATX

Perspective Therapeutics Acquires CGMP-Compliant Manufacturing Facility; Financial Terms Not Disclosed

Lantheus Announces FDA Approval Of DEFINITY For Pediatric Patients

Truist Securities analyst Richard Newitter reiterates Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) with a Buy and raises the price target from $80 to $82.

Reiteration

Truist Securities Reiterates Buy on Lantheus Holdings, Raises Price Target to $82

During the last three months, 4 analysts shared their evaluations of Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>), revealing diverse outlooks from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Lantheus Holdings, presenting an average target of $98.75, a high estimate of $100.00, and a low estimate of $95.00. A 12.61% drop is evident in the current average compared to the previous average price target of $113.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1708711217_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Lantheus Holdings among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$100.00</td>
<td>-</td>
</tr>
<tr>
<td>Justin Walsh</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$95.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Boris Peaker</td>
<td>TD Cowen</td>
<td>Announces</td>
<td>Outperform</td>
<td>$100.00</td>
<td>-</td>
</tr>
<tr>
<td>Kemp Dolliver</td>
<td>Brookline Capital</td>
<td>Announces</td>
<td>Buy</td>
<td>$100.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Lantheus Holdings. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Lantheus Holdings compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Lantheus Holdings's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Lantheus Holdings's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LNTH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Lantheus Holdings analyst ratings.</a>
<h2>Delving into Lantheus Holdings's Background</h2>
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
<h3>Lantheus Holdings: Delving into Financials</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Over the 3 months period, Lantheus Holdings showcased positive performance, achieving a revenue growth rate of 33.71% as of 30 September, 2023. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Lantheus Holdings's net margin excels beyond industry benchmarks, reaching 41.24%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Lantheus Holdings's ROE excels beyond industry benchmarks, reaching 21.09%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Lantheus Holdings's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 9.23%, the company showcases efficient use of assets and strong financial health.
Debt Management: Lantheus Holdings's debt-to-equity ratio stands notably higher than the industry average, reaching 0.88. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Lantheus Holdings: Insights From 4 Financial Analysts

JMP Securities analyst David Turkaly reiterates Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) with a Market Outperform and maintains $100 price target.

JMP Securities Reiterates Market Outperform on Lantheus Holdings, Maintains $100 Price Target

Shares of Etsy, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/etsy#NASDAQ">ETSY</a>) fell sharply during Thursday&rsquo;s session after the company reported <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/02/37261895/4-etsy-analysts-stand-firm-on-ratings-post-q4-earnings-point-to-buyer-growth-fee-ex">mixed fourth-quarter financial results.</a>
Etsy reported quarterly earnings of 62 cents per share which missed the analyst consensus estimate of 78 cents. The company reported quarterly sales of $842.3 million, beating the analyst consensus estimate of $827.81 million. 
Etsy shares dipped 7.5% to $71.34 on Thursday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>La Rosa Holdings Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lrhc#NASDAQ">LRHC</a>) shares jumped 160.7% to $3.6499 after the company said it has acquired a 100% interest in the Company&#39;s franchisee - La Rosa Realty Winter Garden LLC located in Winter Garden, Florida.</li>
<li>BuzzFeed, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bzfd#NASDAQ">BZFD</a>) jumped 91.4% to $0.4150 after the company revealed the sale of Complex Networks to NTWRK, a live-streaming video commerce platform. The deal, valued at $108.6 million, will also result in a 16% reduction in BuzzFeed&rsquo;s workforce.</li>
<li>Monopar Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mnpr#NASDAQ">MNPR</a>) rose 80.7% to $1.03 after the company disclosed promising preclinical data for its MNPR-101 radiopharma program targeting advanced cancers.</li>
<li>Root, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/root#NASDAQ">ROOT</a>) shares gained 40.8% to $12.21 after posting better-than-expected fourth-quarter results.</li>
<li>Novavax, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvax#NASDAQ">NVAX</a>) jumped 34.7% to $5.36. Novavax has reached a settlement related to the 2021 advance purchase agreement for Novavax&#39;s prototype Covid-19 vaccine (NVX-COV2373).</li>
<li>EZFill Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ezfl#NASDAQ">EZFL</a>) rose 34.3% to $1.86. EzFill announced preliminary 2023 revenues of $23 million, up 54% year over year.</li>
<li>Mercurity Fintech Holding Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mfh#NASDAQ">MFH</a>) jumped 30% to $2.93.</li>
<li>Mativ Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/matv#NYSE">MATV</a>) gained 27.6% to $15.00 following upbeat earnings.</li>
<li>Venus Concept Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vero#NASDAQ">VERO</a>) shares climbed 26.9% to $1.6242 after the company received CE Mark from DEKRA Certification B.V. to market Venus Versa Pro in Europe.</li>
<li>Outset Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/om#NASDAQ">OM</a>) gained 26% to $4.0680 following upbeat results.</li>
<li>Ocular Therapeutix, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ocul#NASDAQ">OCUL</a>) rose 22.2% to $9.19 after announcing a $325.0 million private placement.</li>
<li>Remitly Global, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rely#NASDAQ">RELY</a>) shares rose 19.5% to $21.13 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>B. Riley Financial, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rily#NASDAQ">RILY</a>) gained 19.3% to $18.13. B. Riley&rsquo;s board issued a statement regarding internal review.</li>
<li>Super Micro Computer, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smci#NASDAQ">SMCI</a>) jumped 19.2% to $875.07. Supermicro announced a proposed offering of $1.5 billion of convertible senior notes due 2029.</li>
<li>Bone Biologics Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bblg#NASDAQ">BBLG</a>) gained 18.4% to $3.73.</li>
<li>Amylyx Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amlx#NASDAQ">AMLX</a>) rose 17.5% to $18.00 following strong sales results.</li>
<li>ACV Auctions Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acva#NASDAQ">ACVA</a>) gained 16.9% to $16.37 after the company reported better-than-expected fourth-quarter financial results and announced the settlement of its antitrust litigation related to the AutoIMS technology platform.</li>
<li>FTI Consulting, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fcn#NYSE">FCN</a>) jumped 15.5% to $219.72 following upbeat results.</li>
<li>NVIDIA Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvda#NASDAQ">NVDA</a>) rose 15.4% to $778.61 after the company reported better-than-expected fourth-quarter financial results and issued strong revenue guidance for the first quarter.</li>
<li>OUTFRONT Media Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/out#NYSE">OUT</a>) gained 15.4% to $14.35 following upbeat results.</li>
<li>Lantheus Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lnth#NASDAQ">LNTH</a>) rose 14.4% to $64.90 following strong results.</li>
<li>Enerplus Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/erf#NYSE">ERF</a>) rose 13.7% to $18.67.</li>
<li>Indivior PLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/indv#NASDAQ">INDV</a>) gained 13.3% to $19.83 following fourth-quarter results.</li>
<li>Recursion Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rxrx#NASDAQ">RXRX</a>) rose 12.2% to $13.88.</li>
<li>Agile Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/agrx#NASDAQ">AGRX</a>) gained 11.1% to $1.10. Agile Therapeutics was granted extension by Nasdaq Hearings Panel to regain compliance until March 25, 2024. The company sees FY23 revenue of $20 million to $21 million. Agile Therapeutics announces exercise of warrants for $4.8 million gross proceeds.</li>
<li>Synopsys, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/snps#NASDAQ">SNPS</a>) gained 10.7% to $601.93 after the company reported better-than-expected first-quarter adjusted EPS results and issued strong guidance.</li>
<li>Q2 Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qtwo#NASDAQ">QTWO</a>) rose 9.5% to $45.82 following strong results.</li>
<li>Eastside Distilling, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/east#NASDAQ">EAST</a>) shares rose 7.6% to $1.0340.</li>
<li>DigitalOcean Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/docn#NYSE">DOCN</a>) gained 6.8% to $38.29 following upbeat results.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Draganfly Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dpro#NASDAQ">DPRO</a>) shares fell 50.3% to $0.1790 after the company announced pricing of $3.6 million underwritten public offering.</li>
<li>Greenbrook TMS Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gbnh#NASDAQ">GBNH</a>) fell 46.6% to $0.2024 after the company announced a $1.2 million registered direct offering of 6 million shares at $0.20 per share purchase price.</li>
<li>Synaptogenix, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/snpx#NASDAQ">SNPX</a>) shares fell 29.5% to $0.1839 after surging 29% on Wednesday. Synaptogenix received a Notice of Allowance for its U.S. Patent application 17/665,033 titled &quot;Halogenated Esters of Cyclopropanated Unsaturated Fatty Acids for Use in the Treatment of Neurodegenerative Diseases.&quot;</li>
<li>Rivian Automotive, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rivn#NASDAQ">RIVN</a>) fell 26.8% to $11.25 after the company reported a wider-than-expected loss for its fourth quarter and announced plans to reduce its salaried workforce by around 10% to help further improve costs. The company said it sees production of 57,000 vehicles in 2024.</li>
<li>MMTec, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mtc#NASDAQ">MTC</a>) fell 23.2% to $1.0750.</li>
<li>Goosehead Insurance, Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gshd#NASDAQ">GSHD</a>) dipped 21.2% to $68.78 after the company reported worse-than-expected fourth-quarter financial results and issued FY24 revenue guidance below estimates.</li>
<li>Bel Fuse Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/belfa#NASDAQ">BELFA</a>) fell 20.1% to $59.16 after the company reported weak fourth-quarter financial results.</li>
<li>Lucid Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lcid#NASDAQ">LCID</a>) shares fell 19.1% to $2.9912 after the company reported mixed fourth-quarter financial results and issued guidance.</li>
<li>Sunnova Energy International Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nova#NYSE">NOVA</a>) dipped 18.6% to $9.52 after the company reported worse-than-expected fourth-quarter financial results.</li>
<li>ATN International, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atni#NASDAQ">ATNI</a>) declined 18.1% to $29.20 after the company reported fourth-quarter financial results and issued guidance.</li>
<li>Pulmonx Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lung#NASDAQ">LUNG</a>) fell 17.6% to $11.94 after the company reported fourth-quarter financial results.</li>
<li>MGP Ingredients, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mgpi#NASDAQ">MGPI</a>) declined 14.3% to $78.75 after the company reported fourth-quarter financial results.</li>
<li>Momentus Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mnts#NASDAQ">MNTS</a>) shares fell 13.1% to $0.5995 after declining around 7% on Wednesday.</li>
<li>Standard Motor Products, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/smp#NYSE">SMP</a>) dipped 12.7% to $35.01 after the company reported worse-than-expected fourth-quarter financial results and issued guidance.</li>
<li>Teekay Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tk#NYSE">TK</a>) gained 12.4% to $7.21 after the company reported a year-over-year decrease in Q4 financial results.</li>
<li>TrueCar, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/true#NASDAQ">TRUE</a>) dipped 11% to $3.4450 following weak sales.</li>
<li>Kratos Defense &amp; Security Solutions, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ktos#NASDAQ">KTOS</a>) fell 8% to $18.57. Kratos Defense &amp; Security Solutions announced a proposed public offering of $300 million of common stock.</li>
<li>Rogers Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rog#NYSE">ROG</a>) fell 6.8% to $108.29 following weak quarterly results.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/02/37262506/booking-holdings-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earni"> Booking Holdings Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call </a>

Why Etsy Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

U.S. stocks were higher, with the Nasdaq Composite gaining more 2% on Thursday.
Shares of NICE Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nice#NASDAQ">NICE</a>) rose sharply during Thursday&rsquo;s session after the company reported better-than-expected fourth-quarter financial results and <a href="https://www.benzinga.com/news/earnings/24/02/37264405/nices-q4-results-surpasses-expectations-cloud-revenue-soars-sets-bold-2024-targets">issued FY24 guidance above estimates</a>.
NICE reported fourth-quarter fiscal 2023 revenue growth of 9.6% year-over-year to $623.19 million, beating the consensus of $618.51 million. Adjusted EPS improved to $2.36 compared to $2.04 in the prior year, beating the consensus of $2.28.
NICE shares jumped 10.4% to $249.39 on Thursday.
Here are some other big stocks recording gains in today&rsquo;s session.
<ul>
<li>Root, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/root#NASDAQ">ROOT</a>) shares shares rose 40.8% to $12.21 after posting better-than-expected fourth-quarter results.</li>
<li>Novavax, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvax#NASDAQ">NVAX</a>) gained 34.7% to $5.36. Novavax has reached a settlement related to the 2021 advance purchase agreement for Novavax&#39;s prototype Covid-19 vaccine (NVX-COV2373).</li>
<li>Mativ Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/matv#NYSE">MATV</a>) climbed 27.6% to $15.00 following upbeat earnings.</li>
<li>Outset Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/om#NASDAQ">OM</a>) rose 26% to $4.0680 following upbeat results.</li>
<li>Ocular Therapeutix, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ocul#NASDAQ">OCUL</a>) climbed 22.2% to $9.19 after announcing a $325.0 million private placement.</li>
<li>Remitly Global, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rely#NASDAQ">RELY</a>) shares gained 19.5% to $21.13 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>B. Riley Financial, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rily#NASDAQ">RILY</a>) climbed 19.3% to $18.13. B. Riley&rsquo;s board issued a statement regarding internal review.</li>
<li>Super Micro Computer, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smci#NASDAQ">SMCI</a>) gained 19.2% to $875.07. Supermicro announced a proposed offering of $1.5 billion of convertible senior notes due 2029.</li>
<li>AlTi Global, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alti#NASDAQ">ALTI</a>) jumped 18.6% to $6.90. AlTi Global announced a strategic investment of up to $450 million by Allianz X and Constellation Wealth Capital.</li>
<li>Amylyx Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amlx#NASDAQ">AMLX</a>) gained 17.5% to $18.00 following strong sales results.</li>
<li>ACV Auctions Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acva#NASDAQ">ACVA</a>) rose 16.9% to $16.37 after the company reported better-than-expected fourth-quarter financial results and announced the settlement of its antitrust litigation related to the AutoIMS technology platform.</li>
<li>FTI Consulting, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fcn#NYSE">FCN</a>) climbed 15.5% to $219.72 following upbeat results.</li>
<li>NVIDIA Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvda#NASDAQ">NVDA</a>) gained 15.4% to $778.61 after the company reported better-than-expected fourth-quarter financial results and issued strong revenue guidance for the first quarter.</li>
<li>OUTFRONT Media Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/out#NYSE">OUT</a>) climbed 15.4% to $14.35 following upbeat results.</li>
<li>Lantheus Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lnth#NASDAQ">LNTH</a>) gained 14.4% to $64.90 following strong results.</li>
<li>Indivior PLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/indv#NASDAQ">INDV</a>) rose 13.3% to $19.83 following fourth-quarter results.</li>
<li>Installed Building Products, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ibp#NYSE">IBP</a>) gained 12.8% to $228.59 after the company reported better-than-expected fourth-quarter financial results and authorized a $300 million stock repurchase program.</li>
<li>ICON Public Limited Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/iclr#NASDAQ">ICLR</a>) rose 12.1% to $319.05 after the company reported better-than-expected fourth-quarter adjusted EPS results and issued FY24 guidance.</li>
<li>Celestica Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cls#NYSE">CLS</a>) climbed 11.6% to $41.51.</li>
<li>Advanced Micro Devices, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amd#NASDAQ">AMD</a>) rose 11.6% to $183.27 in sympathy with NVIDIA, which reported better-than-expected quarterly financial results and issued revenue guidance above estimates.</li>
<li>Quanta Services, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pwr#NYSE">PWR</a>) gained 11% to $234.42 after the company reported better-than-expected quarterly financial results and issued guidance.</li>
<li>Synopsys, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/snps#NASDAQ">SNPS</a>) climbed 10.7% to $601.93 after the company reported better-than-expected first-quarter adjusted EPS results and issued strong guidance.</li>
<li>Q2 Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qtwo#NASDAQ">QTWO</a>) gained 9.5% to $45.82 following strong results.</li>
<li>Moderna, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrna#NASDAQ">MRNA</a>) gained 9.5% to $95.93 after the company reported fourth-quarter financial results.</li>
<li>Dell Technologies Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dell#NYSE">DELL</a>) rose 8.7% to $88.46.</li>
<li>Wingstop Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wing#NASDAQ">WING</a>) gained 8.4% to $336.34. Wingstop reported better-than-expected results for its fourth quarter on Wednesday.</li>
<li>Royal Caribbean Cruises Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rcl#NYSE">RCL</a>) surged 7.9% to $124.00 after the company raised its FY24 adjusted EPS guidance. Also, the company said demand and bookings has exceeded expectations.</li>
<li>DigitalOcean Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/docn#NYSE">DOCN</a>) rose 6.8% to $38.29 following upbeat results.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/02/37254407/jim-cramer-unity-software-had-problems-but-zscaler-is-a-good-one-to-buy"> Jim Cramer: Unity Software &#39;Had Problems,&#39; But Zscaler Is A &#39;Good One&#39; To Buy </a>

ALTI

DELL

ICLR

NICE

WING

NICE Posts Upbeat Earnings, Joins FTI Consulting, NVIDIA, Moderna And Other Big Stocks Moving Higher On Thursday

Lantheus Holdings shares are trading higher after the company reported better-than-expected Q4 financial results. Also, the company issued Q1 revenue guidance above estimates and FY24 guidance above estimates.

Lantheus Holdings Sees FY24 Revenues Of $1.41B-$1.445B Vs. $1.39B Estimate; Projects FY24 Adjusted EPS Of $6.50-$6.70 Vs. $6.25 Estimate

Lantheus Holdings Expects Q1 Revenues Of $347M-$355M Vs. $336.41M Estimate, Projects Q1 Adjusted EPS Of $1.50-$1.54 Vs. $1.51 Estimate

Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) reported adjusted quarterly earnings of $1.75 per share which beat the analyst consensus estimate of $1.45 by 20.69 percent. This is a 27.74 percent increase over earnings of $1.37 per share from the same period last year. The company reported quarterly sales of $354.00 million which beat the analyst consensus estimate of $342.33 million by 3.41 percent. This is a 34.52 percent increase over sales of $263.17 million the same period last year.

Lantheus Holdings Q4 Adj. EPS $1.75 Beats $1.45 Estimate, Sales $354.00M Beat $342.33M Estimate

KYMR

LASR

LAUR

LILA

MAIN

MELI

MITT

MODV

MORN

MRIN

MRVI

NABL

NMRK

NTLA

NURO

NVCR

NVEE

OLED

ONTF

OPCH

PKST

PLNT

PLYA

PODD

POOL

PRMW

RCEL

RLAY

RMAX

RYTM

SHYF

SMSI

SNBR

SPXC

STWD

TALK

TECK

THRY

TPIC

UPBD

UPLD

VALE

VCYT

VICI

VICR

WTRG

XPEL

ZEUS

Earnings Scheduled For February 22, 2024

Lantheus to supply MK-6240, an investigational F18-labeled PET imaging agent that targets tau tangles &nbsp;
BEDFORD, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced a collaboration agreement with a National Institute on Aging (NIA)-sponsored study called the Consortium for Clarity in ADRD Research Through Imaging (CLARiTI). This agreement enables the consortium to use MK-6240, Lantheus' clinical-stage F18-labeled Positron Emission Tomography (PET) imaging agent, in its investigation of Alzheimer's disease and related dementias. MK-6240 targets aggregated tau protein in the form of neurofibrillary tangles (NFTs) which are a hallmark of several neurodegenerative diseases, including Alzheimer's disease.
The CLARiTI study will involve all 37 Alzheimer's Disease Research Centers in the United States which will recruit 2,000 subjects and collect their imaging and blood-based biomarker data to generate etiologic profiles for cases of mixed dementia.
"This study is designed to shed light on the complex interplay of multiple pathologies contributing to dementia, ultimately advancing our understanding and treatment of this devastating condition," said Sterling Johnson, PhD, Professor of Medicine, University of Wisconsin School of Medicine and Public Health and the CLARiTI study lead. "We are thrilled to partner with Lantheus to use MK-6240 for tau PET imaging in this important study."
"MK-6240 is poised to play a pivotal role in propelling Alzheimer's diagnosis and treatment research to new heights," said Jean-Claude Provost, MD, Chief Medical Officer, Lantheus. "This agreement aligns with Lantheus' purpose to actively cultivate collaborations that empower researchers worldwide with essential tools to accelerate clinical research and development of therapies. In an era defined by an unprecedented number of Alzheimer's diagnoses, the CLARiTI study represents a significant milestone in Alzheimer's research, with the potential to change the trajectory of this degenerative disease."
About the CLARiTI Study Clarity in Alzheimer's Disease and Related Dementias Research Through Imaging (CLARiTI) is a multi-site imaging observational study that will be conducted at all 37 Alzheimer's Disease Research Centers (ADRCs) in the United States. The study will collect data about the presence, absence or change in characteristic disease biomarkers in people who have various types of dementia or are at risk of developing it. CLARiTI is a five-year study that will enroll 2,000 subjects across the U.S. Data generated from CLARiTI will be made available to the scientific community through the National Alzheimer's Coordinating Center, and biological samples will be analyzed and made available through the National Centralized Repository for Alzheimer's Disease and Related Dementias.
Please visit <a href="https://www.globenewswire.com/Tracker?data=WfkCHyfgP3a8NkZjTHD9FsOyV83EvmxZoQI0DpNGxFMhBKh9c2Yue5htAIXMjB6O3B3jEnUIWXftVdEf2GCXfPZPaWZc040rXHNW7wp8CkDLxIDYTMSn8fyAKBLuC9z67dTOU5uNN9_fCOeFGgVB8OhQnVO0IJk8wu77B4KQNZc=">https://naccdata.org/nacc-collaborations/clariti</a> for more information about the study.
About Alzheimer's Disease and Dementia Alzheimer's disease is a progressive degenerative brain disease and the most common form of dementia. Dementia is the loss of cognitive functioning and behavioral abilities to such an extent that it interferes with a person's daily life and activities. Dementia is not a specific disease; it describes a group of symptoms that often has a mixture of etiologies. It is estimated that 6.7 million Americans age 65 and older are currently living with Alzheimer's dementia. As the population ages, it is projected that by 2050, this number may grow to 12.7 million.1

Biotech

General

Lantheus Announces Collaboration To Provide Novel Tau Imaging Agent For Large Consortium Clinical Trial Sponsored By The National Institute On Aging

FHLC: Healthcare Dashboard For April

Yuan Zhi, an analyst from B.Riley Financial, reiterated the Buy rating on Lantheus (LNTH – Research Report). The associated price target was raised...

Buy Rating for Lantheus Holdings with Strong Growth and Acquisition Potential

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Savara (SVRA – Research Report), Johnson & Johnson (...

Analysts Offer Insights on Healthcare Companies: Savara (SVRA), Johnson & Johnson (JNJ) and Lantheus (LNTH)

Lantheus (LNTH) has issued an update. At the recent Annual Meeting of Lantheus Holdings, Inc., several key decisions were passed by the stockholder...

Lantheus Stockholders Approve Key Governance and Compensation Plans

Lantheus Q1 2024 Earnings Preview

Lantheus Non-GAAP EPS of $1.69 beats by $0.15, revenue of $370M beats by $20.81M

CytomX Therapeutics, Allarity Therapeutics, Pulmonx among healthcare movers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Lantheus Holdings (NASDAQ:<a href="https://investorplace.com/stock-quotes/lnth-stock-quote/">LNTH</a>) just reported results for the first quarter of 2024.<ul><li>Lantheus Holdings reported earnings per share of $1.69. This was above the analyst estimate for EPS of $1.54.</li><li>The company reported revenue of $369.98 million.</li><li>This was 6.18% better than the analyst estimate for revenue of $348.45 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/lnth-stock-earnings-lantheus-holdings-for-q1-of-2024/">LNTH Stock Earnings: Lantheus Holdings Beats EPS, Beats Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Lantheus Holdings Stock (NASDAQ:LNTH), Short Interest Report

People Also Watch